Dodulík, J.; Plášek, J.; Kacířová, I.; Uřinovská, R.; Vrtal, J.; Václavík, J.
Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report. Pharmaceuticals 2025, 18, 818.
https://doi.org/10.3390/ph18060818
AMA Style
Dodulík J, Plášek J, Kacířová I, Uřinovská R, Vrtal J, Václavík J.
Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report. Pharmaceuticals. 2025; 18(6):818.
https://doi.org/10.3390/ph18060818
Chicago/Turabian Style
Dodulík, Jozef, Jiří Plášek, Ivana Kacířová, Romana Uřinovská, Jiří Vrtal, and Jan Václavík.
2025. "Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report" Pharmaceuticals 18, no. 6: 818.
https://doi.org/10.3390/ph18060818
APA Style
Dodulík, J., Plášek, J., Kacířová, I., Uřinovská, R., Vrtal, J., & Václavík, J.
(2025). Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report. Pharmaceuticals, 18(6), 818.
https://doi.org/10.3390/ph18060818
